Amicus Therapeutics (FOLD) announced that the European Medicines Agency has granted priority medicines designation to AT-GTX-501, the Company’s investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis

Amicus Therapeutics (FOLD) announced that the European Medicines Agency has granted priority medicines designation to AT-GTX-501, the Company’s investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis

Taysha Gene Therapies has filed proposed terms for a $125 million IPO.The firm is developing gene therapies for various neurodegenerative and other monogenic disease candidates.TSHA is still at a preclinical stage of development for its entire pipeline and the IPO isn't cheap, so may be more suited to long-term hold institutional investors.

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

John Crowley has been the CEO of Amicus Therapeutics, Inc. (NASDAQ:FOLD) since 2011, and this article will examine the...

CRANBURY, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September: * Citi’s 15th Annual BioPharma Virtual Conference on Thursday, September 10, 2020 at 8:55 a.m. E.T. * Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 10:00 a.m. E.T. * Bank of America Global Healthcare Conference on Friday, September 18, 2020 at 4:45 p.m. B.S.T. (11:45 a.m. E.T.)A live audio webcast of each presentation can be accessed via the Investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.CONTACT: Investors: Amicus Therapeutics Andrew Faughnan Director, Investor Relations afaughnan@amicusrx.com (609) 662-3809Media: Amicus Therapeutics Diana Moore Head of Global Corporate Communications dmoore@amicusrx.com (609) 662-5079FOLD–G

Citigroup maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and raises the price target from $15 to $20.

Amicus Therapeutics (NASDAQ:FOLD) affirms FY2020 sales outlook from $250.00 million-260.00 million to $250.00 million-260.00 million.

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 23.08% and -0.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 44.44% year over year to ($0.20), which beat the estimate of ($0.26).Revenue of $62,353,000 rose by

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.26) by 23.08 percent. This is a 44.44 percent increase over losses of $(0.36) per share

Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of  $250M-$260MAT-GAA Phase 3 PROPEL Study Readout and Rolling BLA Submission to U.S. FDA on ScheduleAdvancing Industry-Leading Rare Disease Gene Therapy PortfolioPath to Prof

CRANBURY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

CRANBURY, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss financial results for the second quar

Amicus Therapeutics (NASDAQ:FOLD) inks an agreement with Hayfin Capital Management for a $400M credit facility at 6.5% above LIBOR subject to a 1% floor. T